Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 252
- Registration Number
- NCT02679755
- Locations
- ๐ฎ๐ณ
HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India
๐ฎ๐ณTata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India
๐ฎ๐ณShatabdi Hospital, Nashik, Maharashtra, India
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Oana Danciu, MD
- Target Recruit Count
- 49
- Registration Number
- NCT02668666
- Locations
- ๐บ๐ธ
Penn State Cancer Institute, Hershey, Pennsylvania, United States
๐บ๐ธUniversity of Wisconsin, Madison, Wisconsin, United States
๐บ๐ธUniversity of Nebraska Medical Center, Omaha, Nebraska, United States
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- ๐ฌ๐ง
Royal Devon and Exeter Hospital, Exeter, United Kingdom
๐ฌ๐งUniversity Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
๐ฌ๐งQueen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Hoffman Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT02626507
- Locations
- ๐บ๐ธ
Hoffman Oncology, Bronx, New York, United States
๐บ๐ธCalifornia Research Institute, Los Angeles, California, United States
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT02605486
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
- Conditions
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 131
- Registration Number
- NCT02600923
- Locations
- ๐ง๐ท
Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil
๐ฆ๐ทInstituto de Cardiologia y Cirugia Cardiovascular, Santa Fe, Argentina
๐ง๐ทHospital Da Cidade De Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT02599714
- Locations
- ๐ฌ๐ง
Research Site, London, United Kingdom
Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Thomas Hatschek
- Target Recruit Count
- 10
- Registration Number
- NCT02592083
- Locations
- ๐ธ๐ช
Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 182
- Registration Number
- NCT02592746
- Locations
- ๐ฐ๐ท
Samsung Medical Center, Seoul, Korea, Republic of
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Fondazione Sandro Pitigliani
- Target Recruit Count
- 115
- Registration Number
- NCT02549430
- Locations
- ๐ฎ๐น
Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy
๐ฎ๐นIstituto Europeo Oncologia, Milano, Italy
๐ฎ๐นOspedale Antonio Perrino, Brindisi, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.